692 related articles for article (PubMed ID: 29906570)
1. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
2. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Clark SM; Clemmons AB; Schaack L; Garren J; DeRemer DL; Kota VK
J Oncol Pharm Pract; 2016 Jun; 22(3):416-22. PubMed ID: 25956421
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
[TBL] [Abstract][Full Text] [Related]
4. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Pielichowski W; Barzal J; Gawronski K; Mlot B; Oborska S; Wasko-Grabowska A; Rzepecki P
Transplant Proc; 2011 Oct; 43(8):3107-10. PubMed ID: 21996238
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
[TBL] [Abstract][Full Text] [Related]
8. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
9. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.
Stiff PJ; Fox-Geiman MP; Kiley K; Rychlik K; Parthasarathy M; Fletcher-Gonzalez D; Porter N; Go A; Smith SE; Rodriguez TE
Biol Blood Marrow Transplant; 2013 Jan; 19(1):49-55.e1. PubMed ID: 22863840
[TBL] [Abstract][Full Text] [Related]
10. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of palonosetron, fosaprepitant, and olanzapine as antiemetic prophylaxis for fludarabine and melphalan-based conditioning regimens prior to allogeneic hematopoietic stem cell transplants.
Karpen R; Sen J; Wall S; Musson S; Tossey J
Leuk Res; 2024 Jan; 136():107431. PubMed ID: 38043326
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
Osman AAM; Elhassan MMA; AbdElrahim BHA; Ahmed FHA; Yousif JBH; Ahmed MAM; Abdelhafeez RHA; Ahmed UMY
J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241275
[TBL] [Abstract][Full Text] [Related]
15. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
16. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial.
Radhakrishnan V; Joshi A; Ramamoorthy J; Rajaraman S; Ganesan P; Ganesan TS; Dhanushkodi M; Sagar TG
Pediatr Blood Cancer; 2019 Mar; 66(3):e27551. PubMed ID: 30426714
[TBL] [Abstract][Full Text] [Related]
17. Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.
Ye P; Pei R; Wang T; Cao J; Zhang P; Chen D; Liu X; Du X; Li S; Tang S; Hu Y; Jiang L; Lu Y
Ann Hematol; 2022 Aug; 101(8):1835-1841. PubMed ID: 35668198
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation.
Sakurai M; Mori T; Kato J; Koda Y; Kikuchi T; Kohashi S; Saburi M; Toyama T; Aisa Y; Nakazato T; Beppu N; Tsuda S; Shigematsu N; Okamoto S
Int J Hematol; 2014 Apr; 99(4):457-62. PubMed ID: 24619827
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
20. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Vallejos W; Liang LW; Noga SJ; Rapoport BL
Ann Oncol; 2016 Jan; 27(1):172-8. PubMed ID: 26449391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]